
|Articles|April 27, 2003
Antibody allows physicians to decipher PCa stages
ProstaScint (In-111 capromab pendetide) from Cytogen Corp. is a radiolabeledmonoclonal antibody specific to prostate-specific membrane antigen. Theproduct aids in the staging of prostate cancer, allowing physicians to makecritical distinctions between localized and metastasized disease.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC
2
Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC
3
Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS
4
News Network: Prostate Cancer and Bladder Cancer at ESMO 2025
5